Shilpa Medicare receives USFDA approval for Gemcitabine injection


Shilpa Medicare has received USFDA approval for Gemcitabine injection, used for treatment of various types of cancers. The product Gemcitabine is a generic equivalent of reference listed drug Gemzar.

The drug will produced in the strengths of 200 mg/vial and 1 g/vial and is prescribed for the treatment of ovarian cancer, breast cancer, non-small cell lung cancer and pancreatic cancer. According to market estimates, US market for Gemcitabine for injection USP, 200 mg/vial and 1 g/vial is approximately $11.7 million.

Company Profile : Shilpa Medicare Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.